Certolizumab pegol in the treatment of Takayasu arteritis

Rheumatology
P I NovikovS V Moiseev

Abstract

Certolizumab pegol (CZP) is a PEGylated antigen-binding fragment-fragment of a humanized mAb neutralizing TNF. It lacks Fc-fragment and has a very low potential to cross the placenta. We aimed to report the efficacy and safety of CZP in a case series of patients with refractory Takayasu arteritis (TA). Ten females of reproductive age (18-35 years) with TA were treated with CZP (at a dose of 400 mg at weeks 0, 2 and 4 and at 200 mg every 2 weeks thereafter) for a median of 10 months (range 3-28). Prior to CZP administration all patients received glucocorticoids and ± MTX, CYC, AZA, HCQ, LEF or MMF. Six patients were previously treated with other biological anti-cytokine drugs. The National Institutes of Health criteria and the Indian Takayasu Clinical Activity Score 2010 were used to define disease activity. All patients rapidly responded to treatment with CZP and were able to taper prednisone and MTX doses. Treatment with CZP resulted in a significant decrease in median serum CRP levels and normalization of Indian Takayasu Clinical Activity Score 2010 score in 9 of 10 patients. Remission of systemic vasculitis was achieved in all patients. Seven patients maintained remission for at least 4 months, while one patient developed re...Continue Reading

References

Jun 1, 1994·Annals of Internal Medicine·G S KerrG S Hoffman
Aug 1, 1997·International Journal of Cardiology·B K SharmaF Numano
Apr 17, 2008·Annals of the Rheumatic Diseases·C MukhtyarUNKNOWN European Vasculitis Study Group
Dec 14, 2011·Autoimmunity Reviews·Cloé ComarmondDavid Saadoun
Jan 10, 2012·Rheumatology·Arsène MekinianUNKNOWN Club Rhumatismes et Inflammation, French Vasculitis Study Group and Société Nationale Française de Médecine Interne
Oct 10, 2012·Arthritis and Rheumatism·J C JennetteR A Watts
Dec 4, 2012·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Uma MahadevanMaria T Abreu
Jan 28, 2014·Journal of Autoimmunity·Alexandre Wagner Silva de Souza, Jozélio Freire de Carvalho
Oct 17, 2015·Rheumatology·Daiki Nakagomi, David Jayne
Feb 19, 2016·Annals of the Rheumatic Diseases·Carina Götestam SkorpenMonika Østensen

❮ Previous
Next ❯

Citations

Feb 23, 2019·Modern Rheumatology·Mitsuhiro AkiyamaTsutomu Takeuchi
Sep 6, 2018·Rheumatology International·Stella Pui Yan WongUNKNOWN Hong Kong Takayasu’s arteritis study group
Oct 8, 2020·Clinical and Experimental Medicine·Franco DammaccoRosanna Dammacco
Nov 22, 2018·Current Opinion in Rheumatology·Carlo Salvarani, Gulen Hatemi
Nov 7, 2020·Zeitschrift für Rheumatologie·J H SchirmerB Hellmich

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Aortic Coarctation

Aortic coarctation is a congenital condition characterized by narrowing of the aorta. Discover the latest research on this disease here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.